Nyrada Inc. reported new additional exploratory results of its in vivo cholesterol efficacy study, first announced on 21 December 2020. The study used a mouse model that has been genetically modified to mimic human-like characteristics concerning cholesterol metabolism and cardiovascular health. During the study, 30 mg/kg and 50 mg/kg dose levels were administered over 28 days, with a clear dose-dependent reduction in total cholesterol shown (as previously announced). Nyrada also ran an exploratory group in which animals were treated with 10 mg/kg for 14 days before the dose was increased to 75 mg/kg for the remaining 14 days. A large and rapid reduction in total cholesterol was observed from days 14-28 when the dose increased from 10 mg/kg to 75 mg/kg. Further analysis of the lipoprotein fraction confirms that the reduction in cholesterol is LDL or "bad" cholesterol and that the reduction was dose-dependent. The additional results reported show that Nyrada's lead product candidate NYX-PCSK9i does not affect the body weight, food intake, or liver function of treated animals, while greatly reducing LDL cholesterol levels The data supports the continued development of the Company's hypercholesterolemia clinical candidate towards the clinic. It also confirms the suitability of NYX-PCSK9i as a potential oral treatment that can be combined with a statin in a single pill for the large cohort of patients that cannot reach their targeted LDL cholesterol levels taking a statin alone.